Imaging with a computed tomography or magnetic resonance imaging scan may be needed to confirm the clinical diagnosis.[17] Aggressive debridement with systemic antibiotics targeted at P aeruginosa, and in some cases Aspergillus species, is critical.

Hepatobiliary disorders Skin and subcutaneous tissue disorders Musculoskeletal and connective tissue and bone disorders Reproductive system and breast disorders General disorders Fatigue and administration site conditions Investigations Injury, poisoning and procedural complications *Cross refer to section 4.4.

constipation, oral soft tissue disorder Uncommon pancreatitis, upper gastrointestinal ulcer, oesophagitis, ascites*, anal fissure, dysphagia Rare protein-losing gastroenteropathy, ileus Not known fatal gastrointestinal haemorrhage* Hepatobiliary disorders Uncommon hepatitis, cholecystitis, cholestasis Skin and subcutaneous tissue disorders Very common skin rash d Common alopecia, dermatitis (including eczema), pruritus, acne, dry skin, urticaria, hyperhidrosis Uncommon acute febrile neutrophilic dermatosis, photosensitivity, pigmentation disorder, panniculitis, skin ulcer, bullous conditions, nail disorder, palmar-plantar erythrodysesthe ...[+++]sia syndrome Musculoskeletal and connective tissue disorders Very common musculoskeletal pain Common arthralgia, myalgia, muscular weakness, musculoskeletal stiffness, muscle spasm Uncommon rhabdomyolysis, muscle inflammation, tendonitis Renal and urinary disorders Uncommon renal failure, urinary frequency, proteinuria Reproductive system and breast disorders Uncommon gynecomastia, irregular menstruation General disorders and administration site conditions Very common fluid retention*, fatigue, superficial oedema* e , pyrexia Common asthenia, pain, chest pain, generalised oedema*, chills Uncommon malaise, temperature intolerance Investigations Common weight decreased, weight increased Uncommon blood creatine phosphokinase increased Injury, poisoning, and procedural complications Common contusion

Although definitive data are lacking, drainage alone appears to be a reasonable strategy for methicillin-resistant S aureus skin abscesses, with antibiotics reserved for infants younger than three months of age, or for children who are systemically unwell, have underlying medical problems or have significant surrounding cellulitis.

Pharmacotherapeutic group: Antibacterials for systemic use, Aminoglycoside antibacterials, ATC Code: J01GB01

However, Bronchitol has been used in clinical studies in conjunction with standard cystic fibrosis therapies such as mucolytics, antibiotics (including tobramycin and colistimethate sodium), bronchodilators, pancreatic enzymes, vitamins, inhaled and systemic corticosteroids, and analgesics.